Lifevantage (LFVN) Company Report

LifeVantage acquired LoveBiome, with the deal closing on October 1, 2025, and full integration by November 1, 2025, adding the P84 microbiome blend to its product portfolio.
The company is investing in technology, with a Shopify partnership implementation expected to launch in 2026.
LifeVantage plans further international expansion in 2026, following a successful launch in Iceland in 2025.
For capital allocation in 2026, LifeVantage remains committed to share repurchases, with under $17 million remaining under the existing authorization, and maintaining its dividend.
New study results for Protandim, P84, and MindBody will be announced at the January 2026 global kickoff.

Dec 11, 2025, 7:00 PM

Transcript

LifeVantage Reviews 2025 Performance and Outlines 2026 Strategic Priorities

LFVN

M&A

New Projects/Investments

Share Buyback

LifeVantage completed the LoveBiome acquisition, which officially closed on October 1, 2025, and achieved full integration of LoveBiome consultants into LifeVantage's compensation plan by November 1, 2025.
The company is investing in its technology, including a partnership with Shopify for an e-commerce platform, with a launch anticipated in 2026.
LifeVantage plans further international expansion in 2026, following its recent launch in Iceland in 2025.
Management remains committed to share repurchases, with nearly $17 million remaining under the existing authorization and a 10b5-1 plan effective through June 30, 2025. They also remain committed to their dividend.

Dec 11, 2025, 7:00 PM

Transcript

LifeVantage Reviews 2025 Achievements and Outlines 2026 Strategic and Financial Priorities

LFVN

M&A

New Projects/Investments

Share Buyback

LifeVantage completed the acquisition of LoveBiome on October 1, 2025, fully integrating it by November 1, 2025, and adding the P84 microbiome blend to its product portfolio.
The company is investing in a new Shopify e-commerce platform, with implementation progressing for a 2026 launch, which will lead to slightly elevated CapEx for fiscal year 2026.
LifeVantage launched in Iceland in 2025 and plans further international expansion in 2026.
For 2026, the company remains committed to share repurchases, with just under $17 million remaining under the existing authorization, and to its dividend.

Dec 11, 2025, 7:00 PM

Transcript

LifeVantage Reports Q1 2026 Results, Reiterates Full-Year Guidance, and Details LoveBiome Acquisition

LFVN

Earnings

M&A

Guidance Update

LifeVantage reported net revenue of $47.6 million for Q1 fiscal 2026, a 0.7% increase from the prior year, and adjusted non-GAAP net income of $2.3 million, or $0.18 per diluted share, up from $1.9 million or $0.15 per share in Q1 2025.
Adjusted EBITDA for Q1 2026 was $3.9 million, a decrease from $4.4 million in the prior year, primarily due to lower gross margins and higher commission expenses.
The company successfully closed the LoveBiome acquisition on October 1st, with integration "essentially complete," and expects this acquisition to drive improved operating leverage and contribute to higher second-half fiscal 2026 revenue.
LifeVantage reiterated its fiscal 2026 guidance, projecting full-year revenue between $225 million and $240 million, adjusted non-GAAP EBITDA between $23 million and $26 million, and adjusted non-GAAP EPS between $1.00 and $1.15 per share.
In Q1 2026, the company repurchased 44,000 shares for $600,000 and announced a quarterly cash dividend of $0.045 per share.

Nov 4, 2025, 9:30 PM

Transcript

LifeVantage Corporation Announces Q1 2026 Financial Results

LFVN

Earnings

Guidance Update

Dividends

LifeVantage Corporation reported revenue of $47.6 million for the first fiscal quarter ended September 30, 2025, representing a 0.7% increase from the prior year period. Net income per diluted share was $0.17, and adjusted earnings per diluted share was $0.18.
The company reiterated its fiscal year 2026 guidance, projecting revenue between $225 million and $240 million, adjusted EBITDA of $23 million to $26 million, and adjusted earnings per share in the range of $1.00 to $1.15.
LifeVantage announced a cash dividend of $0.045 per common share, payable on December 15, 2025. Additionally, the company repurchased 44,000 common shares for approximately $0.6 million during the quarter, with $16.7 million remaining under the current repurchase program authorization.
The company highlighted its strategic focus on the acquisition and integration of LoveBiome, aiming to position itself as a leader in natural GLP-1 activation and microbiome health markets.

Nov 4, 2025, 9:06 PM

8-K

LifeVantage Discusses Fiscal Year Performance and Strategic Growth

LFVN

M&A

Product Launch

Share Buyback

LifeVantage (LFVN) reported $229 million in revenue, a 14% increase, and just under $10 million in EBITDA for the fiscal year ended June 30. The company aims for a 12% EBITDA model and maintains a clean balance sheet with approximately $20 million in cash and no debt.
The company recently completed the acquisition of Love Biome, a gut microbiome-focused company, with the transaction closing on October 1 and full integration expected by November 1. This acquisition is projected to be accretive within the first year.
A key product, a natural alternative GLP-1 product, launched about a year ago, has shown clinical results of increasing natural GLP-1 production by over 200% and an average of one pound per week of weight loss over twelve weeks with zero muscle loss.
LifeVantage's business model is characterized by 70% subscription-based revenue and a capital allocation strategy that includes an active share buyback program with $17 million remaining and an annually increasing dividend.

Oct 20, 2025, 9:30 PM

Transcript

LifeVantage Reports FY 2025 Results, Details LoveBiome Acquisition, and Capital Allocation Strategy

LFVN

M&A

Product Launch

Share Buyback

Dividends

LifeVantage reported FY 2025 revenue of $229 million, a 14% increase, and EBITDA just under $10 million, while maintaining a strong balance sheet with $20 million in cash and no debt.
The company completed the acquisition of LoveBiome on October 1, with full integration anticipated by November 1, expecting the transaction to be accretive within the first year.
LifeVantage operates with approximately 80% gross margins and a 70% subscription-based revenue model, supported by a capital allocation strategy that includes an active share buyback program ($17 million remaining) and an annually increasing dividend.
Growth in FY 2025 was primarily driven by the U.S. launch of the MindBody GLP-1 System, with fiscal 2026 guidance provided and international growth from this product expected.

Oct 20, 2025, 9:30 PM

Transcript

LifeVantage Reports FY25 Results and Announces LoveBiome Acquisition

LFVN

M&A

Revenue Acceleration/Inflection

Product Launch

LifeVantage achieved $229 million in revenue and $22 million in EBITDA for fiscal year 2025, marking over 14% revenue growth from FY24, largely due to the MindBody GLP-1 System. The company projects moderate growth in its core business for FY26.
The company announced the acquisition of LoveBiome, a direct selling company specializing in microbiome and gut health, on September 3rd, with closing anticipated on October 1st and full integration by November 1st.
LifeVantage maintains a balanced capital allocation strategy, including a quarterly dividend (which has been increased annually for the past three years and included a special dividend in September 2023) and an active share repurchase program with $17 million remaining under its current authorization.
The MindBody GLP-1 System, a key product, demonstrated an average 11 pounds weight loss and a 9% decrease in overall body fat over a 12-week study, notably with no muscle loss.